For US Healthcare Professionals Only
For US Healthcare Professionals Only
The resources on this page offer information and insights about Jakafi® (ruxolitinib) and treatment of steroid-refractory aGVHD in adult and pediatric patients 12 years and older. Be sure to check back regularly as new materials will be added as they become available.
Oncologist Dr Pashna Munshi discusses the risk of disease progression in SR aGVHD and highlights the importance of early identification and timely intervention.
Oncologist Dr Michael Bishop reviews the primary efficacy data and safety profile from the REACH1 and REACH2 clinical studies evaluating Jakafi in patients with SR aGVHD.
Data from REACH2 are not included in the FDA-approved Prescribing Information for Jakafi. FDA approval for Jakafi for the treatment of SR aGVHD was based on data from the REACH1 study.
Oncologist Dr Pashna Munshi describes how she intervenes early with Jakafi and why she doesn’t let cytopenias deter her.
How I Treat: When to Intervene With Jakafi® (ruxolitinib) in Patients With Steroid-Refractory Acute GVHD and Cytopenias
Pashna Munshi, MD
GVHD Expert
aGVHD=acute graft-versus-host disease; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation; SR=steroid-refractory.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.